Study on Autophagy Maintenance Therapy for Ovarian Cancer Patients

Inclusion Criteria

• Have ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy and has not progressed for at least 6 months.
• Have undergone genetic testing to know BRCA mutation status or similar tests.
• Enroll in the study within 3-8 weeks after the last cycle of platinum-based chemotherapy.
• Have received at least 3 doses of bevacizumab during chemotherapy and plan to continue it.
• Show a positive response to current platinum-based chemotherapy.
• Be 18 years or older.
• Have a performance status score of 0 to 2, indicating good overall health.
• Have specific blood test results within normal limits.
• Agree to use effective birth control during the study and for 6 months after.
• Have stable blood pressure and diabetes if applicable.
• Be able to stop taking statins 48 hours before starting the study.
• Have a normal heart rhythm as shown by an ECG.
• Sign a consent form agreeing to participate in the study.

Exclusion Criteria

• Have severe heart disease or recent heart attack.
• Have a serious mental health condition requiring hospitalization in the last two years.
• Have a significant neurological disorder.
• Have cancer that is resistant to platinum-based treatments.
• Have an active, uncontrolled infection.
• Have had recent radiation, surgery, or experimental treatment within 28 days before starting the study.
• Be unable or unwilling to follow study procedures.
• Be taking certain medications that cannot be stopped.
• Be pregnant or planning to become pregnant during the study.
• Have certain medical conditions like myasthenia gravis or G6PD deficiency.
• Be participating in another clinical trial.
• Have a high cardiovascular risk that requires continued statin use.